期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 189, 期 6, 页码 1171-1181出版社
WILEY
DOI: 10.1111/bjh.16457
关键词
thrombotic microangiopathy; TA-TMA; allogeneic transplantation; allo-HCT
类别
资金
- National Cancer Institute (NCI) [U24CA076518]
- National Heart, Lung and Blood Institute (NHLBI) [U24CA076518]
- National Institute of Allergy and Infectious Diseases (NIAID) [U24CA076518]
- NHLBI [U24HL138660, OT3HL147741, R21HL140314, U01HL128568]
- NCI [U24HL138660, U24CA233032]
- Health Resources and Services Administration (HRSA/DHHS) [HHSH250201700006C]
- Office of Naval Research [N00014-18-1-2888, N00014-17-1-2850]
- Actinium Pharmaceuticals, Inc.
- Adaptive Biotechnologies
- Amgen, Inc.
- Anthem, Inc.
- Astellas Pharma US
- Atara Biotherapeutics, Inc.
- Be the Match Foundation
- bluebird bio, Inc.
- Boston Children's Hospital
- Bristol Myers Squibb Co.
- Celgene Corp.
- Children's Hospital of Los Angeles
- Chimerix, Inc.
- CSL Behring
- CytoSen Therapeutics, Inc.
- Dana Farber Cancer Institute
- Daiichi Sankyo Co., Ltd.
- Fred Hutchinson Cancer Research Center
- Gamida-Cell, Ltd.
- Gilead Sciences, Inc.
- GlaxoSmithKline (GSK)
- HistoGenetics, Inc.
- Immucor
- Incyte Corporation
- Janssen Biotech, Inc.
- Janssen Pharmaceuticals, Inc.
- Janssen Scientific Affairs, LLC
- Jazz Pharmaceuticals, Inc.
- Karius, Inc.
- Karyopharm Therapeutics, Inc.
- Kite, a Gilead Company
- Magenta Therapeutics
- Medac GmbH
- Medical College of Wisconsin
- Mediware
- Merck Company, Inc.
- Mesoblast
- MesoScale Diagnostics, Inc.
- Millennium, the Takeda Oncology Co.
- Miltenyi Biotec, Inc.
- Mundipharma EDO
- National Marrow Donor Program
- Novartis Oncology
- Novartis Pharmaceuticals Corporation
- Omeros Corporation
- Oncoimmune, Inc.
- PCORI
- Pfizer, Inc.
- Phamacyclics, LLC
- PIRCHE AG
- Regeneron Pharmaceuticals, Inc.
- REGiMMUNE Corp.
- Sanofi Genzyme
- Seattle Genetics
- Shire
- Sobi, Inc.
- Spectrum Pharmaceuticals, Inc.
- St. Baldrick's Foundation
- Swedish Orphan Biovitrum, Inc.
- Takeda Oncology
- University of Minnesota
- University of Pittsburgh
- University of Texas-MD Anderson
- University of Wisconsin Madison
- Viracor Eurofins
Transplant-associated thrombotic microangiopathy (TA-TMA) is a complication of allogeneic transplantation (allo-HCT). The incidence and risk factors associated with TA-TMA are not well known. A retrospective analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) was conducted including patients receiving allo-HCT between 2008 and 2016, with the primary objective of evaluating the incidence of TA-TMA. Secondary objectives included identification of risk factors associated with TA-TMA, and the impact of TA-TMA on overall survival and the need for renal replacement therapy (RRT). Among 23,665 allo-HCT recipients, the 3-year cumulative incidence of TA-TMA was 3%. Variables independently-associated with increased incidence of TA-TMA included female sex, prior autologous transplant, primary disease (acute lymphoblastic leukaemia and severe aplastic anaemia), donor type (mismatched or unrelated donor), conditioning intensity (myeloablative), GVHD prophylaxis (sirolimus + calcineurin inhibitor), pre-transplant kidney dysfunction and acute GVHD (time-varying effect). TA-TMA was associated with higher mortality (HR = 3 center dot 1, 95% Confidence Interval [CI] = 2 center dot 8-16 center dot 3) and RRT requirement (HR = 7 center dot 1, 95% CI = 5 center dot 7-311 center dot 6). This study provides epidemiologic data on TA-TMA and its impact on transplant outcomes. Increased awareness of the risk factors will enable providers to be vigilant of this uncommon but serious transplant complication. The results will also provide benchmarking for future study designs and comparisons.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据